Kamada Sets March 11, 2026 Date to Report Fiscal 2025 Results

Kamada ( (IL:KMDA) ) has shared an announcement.

Kamada Ltd., a global biopharmaceutical company specializing in plasma-derived therapies for rare and serious conditions, markets a suite of FDA-approved products and equine-based anti-snake venoms while also distributing in-licensed drugs, including biosimilars, in Israel and MENA. The company is building out its plasma collection network in Texas and seeking strategic deals to extend its product reach and sustain profitability.

On March 4, 2026, Kamada announced it will report financial results for the fourth quarter and full fiscal year ended December 31, 2025, before U.S. markets open on March 11, 2026. Management will host an investment community conference call and live webcast that morning, signaling an upcoming update on the firm’s operational performance and strategic progress that will be closely watched by investors and other stakeholders.

The most recent analyst rating on (IL:KMDA) stock is a Buy with a ILs2842.00 price target. To see the full list of analyst forecasts on Kamada stock, see the IL:KMDA Stock Forecast page.

More about Kamada

Kamada Ltd. is a global biopharmaceutical company focused on specialty plasma-derived therapies and treatments for rare and serious conditions. Its portfolio includes six FDA-approved plasma products such as KEDRAB, GLASSIA, CYTOGAM, VARIZIG, WINRHO SDF and HEPAGAM B, along with KAMRAB and equine-based anti-snake venom therapies. The company also distributes in-licensed pharmaceuticals, including biosimilars, in Israel and the MENA region. Kamada is expanding U.S. plasma collection operations with three centers in Texas and pursues M&A and collaboration opportunities to broaden its marketed portfolio and support long-term profitable growth.

Average Trading Volume: 107,981

Technical Sentiment Signal: Strong Buy

Current Market Cap: ILs1.57B

See more insights into KMDA stock on TipRanks’ Stock Analysis page.